BIOMARIN PHARMACEUTICAL INC

NASDAQ: BMRN (BioMarin Pharmaceutical Inc.)

Last update: 5 hours ago

58.54

0.44 (0.76%)

Previous Close 58.10
Open 58.02
Volume 44,406
Avg. Volume (3M) 2,091,910
Market Cap 11,226,931,200
Price / Earnings (TTM) 21.68
Price / Earnings (Forward) 13.76
Price / Sales 3.86
Price / Book 1.92
52 Weeks Range
52.93 (-9%) — 94.85 (62%)
Earnings Date 4 Aug 2025
Profit Margin 17.76%
Operating Margin (TTM) 30.05%
Diluted EPS (TTM) 2.70
Quarterly Revenue Growth (YOY) 14.80%
Quarterly Earnings Growth (YOY) 109.40%
Total Debt/Equity (MRQ) 10.39%
Current Ratio (MRQ) 5.52
Operating Cash Flow (TTM) 700.26 M
Levered Free Cash Flow (TTM) 411.56 M
Return on Assets (TTM) 6.38%
Return on Equity (TTM) 9.64%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock BioMarin Pharmaceutical Inc. Bearish Bearish

AIStockmoo Score

0.5
Analyst Consensus 3.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages -1.0
Technical Oscillators 2.0
Average 0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BMRN 11 B - 21.68 1.92
ARGX 35 B - 34.16 6.24
WVE 1 B - - 6.29
VRTX 118 B - - 7.15
INCY 13 B - 338.35 3.55
REGN 58 B 0.33% 13.67 2.01

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Sector Healthcare
Industry Biotechnology
Investment Style Mid Growth
% Held by Insiders 0.77%
% Held by Institutions 98.91%

Ownership

Name Date Shares Held
Primecap Management Co/Ca/ 31 Mar 2025 17,773,281
Dodge & Cox 31 Mar 2025 14,955,240
Viking Global Investors Lp 31 Mar 2025 10,800,059
Capital Research Global Investors 31 Mar 2025 9,150,655
Ameriprise Financial Inc 31 Mar 2025 4,207,563
Norges Bank 31 Dec 2024 3,569,831
Elliott Investment Management L.P. 31 Mar 2025 3,500,338
Aqr Capital Management Llc 31 Mar 2025 2,925,805
Deutsche Bank Ag\ 31 Mar 2025 1,887,353
52 Weeks Range
52.93 (-9%) — 94.85 (62%)
Price Target Range
78.00 (33%) — 104.00 (77%)
High 104.00 (Goldman Sachs, 77.65%) Buy
Median 91.00 (55.44%)
Low 78.00 (Citigroup, 33.24%) Hold
Average 91.00 (55.44%)
Total 1 Buy, 1 Hold
Avg. Price @ Call 62.05
Firm Date Target Price Call Price @ Call
Goldman Sachs 05 May 2025 104.00 (77.65%) Buy 62.06
Citigroup 02 May 2025 78.00 (33.24%) Hold 62.03

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria